Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
PRECISION BIOSCIENCES INC (DTIL)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/21/2023 |
8-K/A
| Financial Statements and Exhibits Interactive Data|
Docs:
|
"Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. ASSET PURCHASE AGREEMENT BY AND AMONG PRECISION BIOSCIENCES, INC., IMUGENE INC. and IMUGENE LIMITED August 15, 2023",
"Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT by and between IMUGENE INC. and PRECISION BIOSCIENCES, INC. LICENSE AGREEMENT This License Agreement is entered into as of August 15, 2023 , by and between Precision BioSciences, Inc., a corporation organized and existing under the laws of Delaware, having an address at 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701, U.S.A. , and Imugene Inc., a corporation organized and existing under the laws of Nevada, with its principal business office located at Suite 200, 701 South Carson St, Carson City, Nevada 89701, U.S.A. . Imugene and Precision are each hereafter referred to individually...",
"Precision BioSciences, Inc. Unaudited Pro Forma Condensed Consolidated Financial Statements On August 15, 2023, Precision BioSciences, Inc. entered into an Asset Purchase Agreement with Imugene Limited, an Australian corporation , and its wholly owned subsidiary Imugene Inc. , a Nevada corporation . Pursuant to and simultaneously with the execution of the Purchase Agreement, on August 15, 2023 , Imugene US acquired the manufacturing infrastructure to the Company’s CAR T program that uses azer-cel for the potential treatment of relapsed or refractory non-Hodgkin lymphoma, which includes the Company’s MCAT facility, certain contracts of the Company with respect to the MCAT facility and the Company’s azer-cel program, including the lease to the MCAT facility, and related equipment, supplies, ..." |
|
| 08/04/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. EXECUTION VERSION amended and restated DEVELOPMENT AND LICENSE AGREEMENT between PREVAIL THERAPEUTICS INC. and PRECISION BIOSCIENCES, INC. AMENDED AND RESTATED Development AND LICENSE AGREEMENT This Amended and Restated Development and License Agreement entered into as of June 30, 2023 , by and between Precision BioSciences, Inc., a corporation organized and existing under the laws of Delaware, having an address at 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701, U.S.A. , and Prevail Therapeutics Inc., a corporation organized and existing under the laws of Delaware, with its principal business office..." |
|
| 06/16/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 06/09/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 06/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/31/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 04/27/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/18/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/23/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/23/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/09/2023 |
8-K
| Quarterly results |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 02/27/2023 |
SC 13G
| GREAT POINT PARTNERS LLC reports a 7.3% stake in Precision BioSciences Inc. |
| 02/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/14/2023 |
SC 13G/A
| GREAT POINT PARTNERS LLC reports a 3.4% stake in Precision BioSciences Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/27/2023 |
SC 13G/A
| ELI LILLY & Co reports a 3.4% stake in * Precision BioSciences, Inc. |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ... |
| 11/10/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/08/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/02/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/31/2022 |
SC 13G/A
| JANTZ DEREK reports a 3.9% stake in Precision BioSciences, Inc. |
| 08/26/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|
|
|